Pramodini Medicare Limited is an established diagnostic service provider in India. The company provides a comprehensive range of technology-enabled diagnostic services, encompassing radiology, clinical laboratory, and nuclear medicine services, to public hospitals, private hospitals, certain Public Sector Undertakings (PSUs) of the Government of India, and medical colleges across tier I, tier II, and tier III cities. Its core value proposition is built upon providing high-quality, accurate, and cost-effective testing services through a robust and integrated digital infrastructure. Under its primary business model, the company partners with public and private entities to establish onsite diagnostic facilities, maximizing patient reach by utilizing existing healthcare networks and generating consumption-based fee revenues.
The company caters to a highly diversified and institutional customer base split across Business-to-Government (B2G), Business-to-Business (B2B), and Business-to-Consumer (B2C) segments. In Fiscal 2026, the B2G segment (primarily Public-Private Partnerships) was the largest driver of business, representing 61.46% (Rs 38.28 Cr) of total operating revenues, followed by B2B at 20.82% (Rs 12.97 Cr), and B2C standalone centres at 17.72% (Rs 11.04 Cr). Geographically, the company operates a network of 16 diagnostic centres located across 7 states and 14 cities in India, with domestic sales in Andhra Pradesh accounting for the largest regional concentration at 61.90% of Fiscal 2026 revenue.
Pramodini’s extensive diagnostic and clinical service infrastructure supports a high volume of complex medical testing. As of Fiscal 2026, the company’s operations are supported by an advanced asset base that includes 8 CT scanners, 7 MRI machines, 20 X-ray units, 15 ultrasound machines, 1 PET-CT scanner, 2 mammography systems, 2 Dexa scans, 6 CR systems, and 3 DR systems. Instead of industrial factories, its capacity and operational efficiency are measured by test volumes, which scaled rapidly to 4,74,419 total tests conducted in Fiscal 2026, up from 2,54,765 in Fiscal 2025 and 2,39,726 in Fiscal 2024. Radiology remained the dominant service line, contributing 97.05% of operational revenues in Fiscal 2026.
A major cornerstone of the company’s competitive moat is its highly qualified medical panel and technology-driven infrastructure. The management team is led by individual promoters Dr. Chalasani Kuldeep Kumar (Chairman and Managing Director), who possesses more than two decades of experience in Radio-Diagnosis, and Dr. Chalasani Kavitha (Non-Executive Director), who has over two decades of experience as an obstetrician and gynaecologist. The company has integrated cloud-based IT networks to facilitate rapid tele-radiology reporting and has entered into a Letter of Intent to expand its geographical footprint further by establishing a proposed new diagnostic hub in Bangalore, Karnataka.
Financial Performance & Valuation Analysis As per financial performance, Pramodini Medicare Limited has posted total income / net profits of Rs 35.79 Cr / Rs 6.93 Cr (FY24), Rs 38.55 Cr / Rs 11.03 Cr (FY25) and Rs 63.38 Cr / Rs 17.38 Cr (FY26). So as per previous financials data, the company has shown exceptional top-line and bottom-line growth with Total Income expanding at a 33.02% CAGR, while its total borrowings increased to Rs 17.85 Cr in FY26 from Rs 10.81 Cr in FY25, though reduced from Rs 11.96 Cr in FY24. Company has an average EPS of Rs 7.13 (weighted average EPS is Rs 8.15) and average RoNW of 30.51% (weighted average RoNW is 31.29%) for the last three fiscals. Based on the pre-issue book value, the issue is priced at a Pre-Issue P/BV of 3.71 as per NAV of Rs 31.84 as on 31.03.26. Factoring in the fresh issue proceeds of Rs 63.14 Cr, the Post-Issue P/BV stands at 2.24. If we attribute the latest earnings of FY24, FY25, and FY26 to the expanded equity base post-issue (~2.20 Cr shares), then the asking price is at a Post-Issue P/E of around 37.54, 23.59, and 14.97 respectively. As per RHP, a comparison between listed peers shows Invicta Diagnostic trading at a P/E of 13.62, Krsnaa Diagnostics at 16.74, and Star Imaging & Path Labs at 7.87, which positions the company's asking price of 14.97x FY26 P/E at a highly competitive valuation relative to Krsnaa Diagnostics given its superior return ratios.
BRLM & Track Record On BRLM's front, Smart Horizon Capital Advisors Private Limited is associated with this IPO, and the Lead BRLM has handled 26 IPOs in the last three fiscal years. (Data as on current date in document).
✍️ Post a Comment